Skip to main
BLTE
BLTE logo

BLTE Stock Forecast & Price Target

BLTE Analyst Ratings

Based on 5 analyst ratings
Strong Buy
Strong Buy 60%
Buy 40%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Belite Bio Inc. is positioned favorably in the biopharmaceutical market due to its innovative approach to treating severe eye diseases and metabolic disorders, with positive expectations set for upcoming updates from the Phase 3 trials of its drug, tinlarebant, which are expected to drive share appreciation. The recent increase in the sample size of the PHOENIX trial indicates a robust commitment to achieving reliable results, while the increased investor attention following the interim analysis of the DRAGON trial suggests a growing confidence in the company's potential for successful outcomes. Additionally, the solid cash position and improved estimates for tinlarebant's pricing and STGD1 prevalence further enhance the optimism surrounding the company's financial outlook and prospects for market approval.

Bears say

Belite Bio Inc reported a significant net loss of $36.1 million in 2024, raising concerns about its financial sustainability amid ongoing clinical trials. The company faces substantial risks related to its lead candidate, tinlarebant, including potential failures in clinical trials, regulatory approval, and competition, which could severely impact its ability to achieve commercial success. Moreover, regulatory uncertainties and the possibility of dilution further exacerbate the negative outlook on the company's stock.

BLTE has been analyzed by 5 analysts, with a consensus rating of Strong Buy. 60% of analysts recommend a Strong Buy, 40% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Belite Bio Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Belite Bio Inc (BLTE) Forecast

Analysts have given BLTE a Strong Buy based on their latest research and market trends.

According to 5 analysts, BLTE has a Strong Buy consensus rating as of Jul 24, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $71.60, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $71.60, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Belite Bio Inc (BLTE)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.